Colon Cancer Diagnosis and Therapy Vol. 3

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide.  Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis.

This book is the third of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.

Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his MSc and PhD, both in biotechnology from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his D.Sc. from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju's research focuses on translational research in gastrointestinal malignancies. He has published over 90 research papers in highly respected international journals and has presented more than 50 abstracts at various national and international conferences. He is author and editor of several books. Dr. Nagaraju is an editorial board member of several internationally recognized academic journals, and is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He is a member of the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), the Science Advisory Board, The RNA Society and the American Association of Cancer Research (AACR).Dr. Dhananjay Shukla is an Assistant Professor in the Department of Biotechnology at Guru Ghasidas Vishwavidyalaya (A Central University) in India. Dr. Shukla received his PhD in Biotechnology from Jamia Hamdard University. He is a member of the Indian Immunological Society and Indian Science Congress. He has presented and been invited to lecture at a number of national meetings in India.
Dr. Naveen Kumar Vishvakarma is an Assistant Professor in the Department of Biotechnology at Guru Ghasidas Vishwavidyalaya (A Central University) in India. Dr. Vishvakarma received his PhD in Biotechnology from Banaras Hindu University. He has written a number of book chapters and been invited to lecture at a dozens of national meetings in India.